Enliven Therapeutics, Inc. (ELVN) Misses Q1 EPS by 23c

Enliven Therapeutics, Inc. (NASDAQ: ELVN) reported Q1 EPS of ($0.80), $0.23 worse than the analyst estimate of ($0.57).

For earnings history and earnings-related data on Enliven Therapeutics, Inc. (ELVN) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Sunstone Hotel Investors to sell Hyatt Regency San Francisco for $279M
• UBS Reiterates Buy Rating on General Motors (GM) as Defense Opportunity in Focus